Issues lobbied + lobbyists
MMM — Medicare/Medicaid
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Lobbyists: AMELIA SUERMANN; THOMAS FOULKES; ISABEL OMER [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Lobbyists: AMELIA SUERMANN; THOMAS FOULKES; ISABEL OMER [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
BUD — Budget/Appropriations
Appropriations for the Department of Health & Human Services, the Department of Veterans Affairs, and the Department of Defense.
Lobbyists: AMELIA SUERMANN; THOMAS FOULKES; ISABEL OMER [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
VET — Veterans
Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.
Lobbyists: AMELIA SUERMANN; THOMAS FOULKES [new]; ISABEL OMER [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TAR — Tariff (miscellaneous tariff bills)
Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.
Lobbyists: AMELIA SUERMANN; THOMAS FOULKES; ISABEL OMER [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE